Elias Jabbour, ASH 2021: Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (PACE and OPTIC Trials)
We were delighted to catch up with editorial board member Prof Elias Jabbour (MD Anderson Cancer Center, Houston, TX, USA) to discuss his presentation at the American Society of Hematology (ASH) Annual Meeting on dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia from the PACE and Optic trials.
1. What are the unmet needs in the management of patients with treatment-resistant chronic-phase chronic myeloid leukemia? 00:11-00:40
2. Could you tell us a little about ponatinib and the clinical evidence supporting its use in this treatment setting? 00:40-01:24
3. What were the objectives of the analysis of data from the PACE and OPTIC trials? 01:24-02:36
4. What were the efficacy findings from the dose reduction strategies of the two studies? 02:38-03:48
5. What are the clinical implications of these findings and what further research is needed? 03:48-04:30
Speaker Disclosure: Elias Jabbour has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 63rd ASH Annual Meeting & Exposition
Share this Video
Related Videos In Leukaemia
Massimo Breccia, ASH 2022: Asciminib for patients with chronic myeloid leukaemia, the ASC4OPT study
The ASC4OPT study aims to potentially optimize dosing levels of asciminib in patients with chronic myeloid leukaemia in the chronic phase that have previously been treated with 2 lines of tyrosine kinase inhibitors. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the ASCEMBL findings, what we […]
Massimo Breccia, ASH 2022: The limitations of tyrosine kinase inhibitors in chronic myeloid leukaemia and approval status of asciminib
Tyrosine kinase inhibitors (TKIs) are the standard of care in the treatment of chronic myeloid leukaemia (CML). Asciminib is the first BCR::ABL1 inhibitor that functions by specifically targeting the ABL myristoyl pocket. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the limitations of TKIs in the […]
Jorge Cortes, ASH 2022: IDH1 inhibitors in the treatment of IDH1-mutant acute myeloid leukaemia – results from a phase II pivotal clinical trial
Professor Jorge Cortes (Georgia Cancer Center, GA, USA) discusses the results from a recent clinical trial that were presented at ASH 2022. Abstract 2757: ‘Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial‘ Disclosures: Jorge Cortes is a […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!